The 2026 Evidence Pack: What Human Trials Actually Show for Rapamycin and NAD+

For decades, the science of longevity has been trapped in a frustrating paradox: researchers could reliably extend the lifespan of mice, worms, and yeast, but translating those breakthroughs to humans remained elusive. The year 2026 marks a definitive shift in this narrative. The longevity field has officially transitioned from preclinical animal models to rigorous human clinical trials. Rather than chasing the impossible metric of a forty-year human lifespan study, scientists are now measuring "healthspan"—the preservation of immune resilience, cardiovascular function, and cellular repair. At the forefront of this clinical revolution are two highly debated interventions: mTOR inhibitors, primarily rapamycin, and NAD+ precursors like NMN and NR.[7]

The biological premise behind these compounds is compelling. As the human body ages, fundamental cellular mechanisms begin to fail. The mTOR pathway, which regulates cell growth and nutrient sensing, becomes hyperactive, driving cellular exhaustion and inflammation. Simultaneously, levels of NAD+—a critical coenzyme required for mitochondrial energy production and DNA repair—plummet. By inhibiting mTOR with low-dose rapamycin and boosting NAD+ with oral precursors, researchers hypothesize that we can trick the body into a state of youthful cellular maintenance. But until recently, the human evidence was largely anecdotal, driven by biohackers and off-label prescriptions.[6][7]

Rapamycin is arguably the most robust life-extending drug ever tested in a laboratory. Originally approved by the FDA as an immunosuppressant to prevent organ transplant rejection, it has consistently extended the lifespan of every model organism it has been tested on, often by 10 to 25 percent. However, the distance between a genetically identical laboratory mouse and a human being is vast. To bridge this gap, the longevity community eagerly awaited the results of the PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), the first long-term, randomized, placebo-controlled trial of the drug in healthy older adults.[1][6]

Published in the journal Aging in 2025, the 48-week PEARL trial enrolled 114 healthy adults aged 50 to 85. Participants received either a placebo, 5 mg of rapamycin weekly, or 10 mg weekly. The results offered a nuanced reality check: the trial missed its primary endpoint, showing no significant reduction in visceral fat. However, the secondary endpoints revealed striking, sex-specific benefits. Women taking the 10 mg weekly dose experienced significant improvements in lean tissue mass and reported a measurable reduction in chronic pain. Meanwhile, participants in the 5 mg group reported statistically significant improvements in emotional well-being and general health.[1]

Perhaps the most crucial finding from the PEARL trial was its safety profile. Over the course of nearly a year, low-dose, intermittent rapamycin administration proved to be safe and well-tolerated in normative-aging adults. Serious adverse events were reported at similar rates across both the placebo and intervention groups, with the most common minor side effect being mild gastrointestinal discomfort. This data effectively dismantles the long-held fear that low-dose rapamycin would dangerously suppress the immune systems of healthy adults, clearing the runway for larger, more targeted Phase 3 clinical trials.[1][6]

In fact, emerging evidence suggests that rather than suppressing the immune system, intermittent rapamycin might actually rejuvenate it. A landmark 2026 study published in Aging Cell by researchers at the University of Oxford and the University of Nottingham investigated how mTOR inhibition affects T cells—the white blood cells responsible for fighting off infections and clearing out damaged tissue. As we age, T cells accumulate DNA damage, specifically double-strand breaks, leading to immune dysfunction and systemic inflammation.[2]

The Oxford study revealed that hyperactivation of the mTOR pathway directly correlates with this severe DNA damage in older adults. When researchers treated damaged human T cells with rapamycin, the results were dramatic: the drug significantly reduced DNA double-strand breaks and doubled the survival rate of the immune cells, jumping from a 20 percent survival rate in the placebo group to 60 percent. By protecting these vital immune cells from genomic instability, rapamycin appears to enhance the body's resilience against the fundamental drivers of aging.[2]

Beyond the immune system, rapamycin is showing promise in reversing age-related cardiovascular decline. A 2025 proof-of-concept pilot study published in GeroScience administered 1 mg of rapamycin daily for eight weeks to healthy older men. Despite the short duration, the researchers observed significant improvements in cardiac diastolic function and endothelial health. The speed of these cardiovascular improvements suggests that mTOR inhibition physically rejuvenates the vascular system, providing preliminary human evidence that aligns perfectly with decades of geroprotective data in animal models.[3]

While rapamycin targets the mTOR pathway, the other half of the longevity clinical push focuses on cellular energy, specifically NAD+ (Nicotinamide Adenine Dinucleotide). NAD+ is essential for the function of sirtuins—often dubbed "longevity genes"—and for mitochondrial health. Because NAD+ levels drop precipitously as we age, a massive commercial market has erupted around NAD+ precursors, primarily Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN). But separating the aggressive commercial marketing from the actual clinical science has been a major challenge for physicians and patients alike.[7]

To cut through the noise, a massive 2026 PRISMA systematic review published in Ageing Research Reviews synthesized the data from 113 eligible studies, including 33 human intervention trials. The review confirmed one undeniable biological fact: oral supplementation with NMN or NR consistently and dose-dependently raises blood NAD+ levels across diverse human populations. The biological mechanism works exactly as intended, successfully restoring this critical coenzyme to more youthful levels without severe side effects.[4]

However, the systematic review also highlighted a critical caveat: while we can reliably raise NAD+ levels, translating that biochemical change into proven clinical anti-aging outcomes remains complex. The evidence for general muscle function improvement or broad physical rejuvenation in healthy adults is currently weak. Instead, the most promising clinical applications for NAD+ precursors are highly targeted. A 2025 consensus review in Nature Aging identified neurodegeneration, chronic inflammation, and sensory decline as the areas where NAD+ restoration shows the most profound clinical potential.[4][5]

This targeted potential was vividly demonstrated in the recent NR-SAFE randomized trial, which focused on Parkinson's disease. Patients receiving a high dose of 3,000 mg/day of Nicotinamide Riboside over four weeks showed a significant 10.7-point decrease in their clinical disease scores, compared to no change in the placebo group. While the sample size was small, it underscores the emerging consensus in longevity medicine: these compounds may be most effective when used to treat specific age-related metabolic or neurological deficits, rather than as blanket preventative supplements for perfectly healthy young adults.[7]

The 2026 evidence also provides a stark warning regarding delivery methods. While oral NAD+ precursors have a moderate and growing clinical evidence base, the highly lucrative market for intravenous (IV) NAD+ therapy—often sold in wellness clinics for hundreds of dollars per session—currently lacks rigorous randomized controlled trial support for anti-aging indications. The scientific community is urging a pivot back to the data, emphasizing that biological activity in a petri dish does not automatically equal clinical benefit in an IV drip.[7]

Ultimately, the 2026 data landscape for human longevity trials is one of cautious, evidence-backed optimism. We are moving past the era of biohacker guesswork and into an age of standardized clinical evaluation. With massive Phase 3 trials like the $38 million VITAL-H study now actively randomizing healthy adults to rapamycin, the next five years will likely yield definitive answers on disease prevention. For now, the evidence confirms that while we haven't found a magic pill for immortality, we have successfully identified safe, active compounds that can measurably improve the resilience of the aging human body.[6][7]